Where does Akebia Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Akebia Therapeutics, Inc. ranks #11,903 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Akebia Therapeutics, Inc. hold?

Akebia Therapeutics, Inc. holds 25 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Akebia Therapeutics, Inc.'s Innovation Score?

Akebia Therapeutics, Inc. has an Innovation Score of 38.0 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Akebia Therapeutics, Inc. focus on?

Akebia Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 23 patents, ranking #383 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Akebia Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Akebia Therapeutics, Inc.'s recent grant velocity is +30% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Akebia Therapeutics, Inc.'s patents?

Akebia Therapeutics, Inc.'s patents average 13.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Akebia Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Akebia Therapeutics, Inc.

USPTO PatentsView assignee record - 25 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Akebia ranks #11,903 of 49,997 tracked US assignees by granted-patent volume, with 25 patents across 6 technology areas.

#11,903
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.0/100): 13.6
avg claims per patent: +30%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11903 · US Corporation #11,903 · 25 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 25 grants
UPPER-Q #11,903/49,997
PHOTO-FINISH Adeia Imaging
CPC-NARROW C07D · 6 areas
INNOV-THIN 38.0/100
CLAIMS-RICH 13.6 claims/avg
TYPE-USCORP US Corporation
VEL-UP +30% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Adeia Imaging LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Akebia’s 38.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.3 pts (30%) Velocity 10.0 pts (26%) Breadth 8.7 pts (23%) Claim depth 8.1 pts (21%)

Qualcomm Incorporated · highest

85
Akebia Therapeutics · this assignee

38
Caribou Biosciences · near

38
Fractilia · near

38
Opel Solar · near

38
Guangdong Virtual… · near

38
3D Lighting… · lowest

7

What this shows Akebia's Innovation Score is 38.0/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Akebia?

Each dot is one of Akebia’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Akebia’s own 13.6 claims/patent is at or below the 15.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Akebia vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Akebia's grants concentrate

Akebia Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 92% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2021. By volume, Akebia sits between Adeia Imaging LLC and Alpine Electronics of Silicon Valley, Inc..

Akebia's three-year grant acceleration

Akebia Therapeutics, Inc. shows 9 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Adeia Imaging

25
Advanced Elemental

25
Aeroflex Colorado…

25
Air Water

25
Albany Medical Co…

25
Alkahest

25
Alphasense Oy

25
Alpine of Silicon…

25
Akebia Therapeuti… ◀

25

What this shows Akebia holds 25 patents at rank #11,918, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Akebia

By rank, the assignees closest to #11,918 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Akebia's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Akebia, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Akebia ranks #383 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Opel Solar, Inc. 38 Fractilia, LLC 38 Caribou Biosciences, Inc. 38 Guangdong Virtual Reality Technology Co., Ltd. 38

Akebia's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Akebia Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	8.0%
2017	3	12.0%
2018	3	12.0%
2019	2	8.0%
2020	3	12.0%
2021	1	4.0%
2022	4	16.0%
2023	3	12.0%
2024	2	8.0%
2025partial year	2	8.0%

Which technologies does Akebia Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 23

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 21

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 16

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 7

C07C - Acyclic OR Carbocyclic Compounds 5

Y02A - Technologies FOR Adaptation TO Climate Change 5

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Akebia Therapeutics, Inc.'s patent record in context - here's where to go next.

Akebia Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 92% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #11,903 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Akebia Therapeutics, Inc. against Adeia Imaging LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.